Companies ›Healthcare ›ICU.O

ICU.O — NASDAQ Diversified Medical Equipment & Supplies

SeaStar Medical Holding Corp

$4,22

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

16,9M USD

P/E

—

EV / Rev

16,9x

Div yield

—

Op margin

—

ROE

283,9 %

Net margin

—

Debt / equity

-0,91

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$3,59

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

SeaStar Medical Holding Corp develops and commercializes medical devices, primarily focused on the urology and surgical markets, generating revenue through product sales and licensing agreements.

Business. SeaStar Medical Holding Corp (NASDAQ: ICU.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, focusing on capital equipment and consumables for medical procedures. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NASDAQ stock exchange under the ticker symbol ICU.O.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target9,00

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

9,00

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

283,9 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ICU.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ICU.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

SeaStar Medical Holding Corp (NASDAQ: ICU.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, focusing on capital equipment and consumables for medical procedures. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NASDAQ stock exchange under the ticker symbol ICU.O.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

SeaStar Medical Holding Corp operates with a negative equity position of -$4.47 million and a debt-to-equity ratio of -0.91, indicating a leveraged capital structure with liabilities exceeding assets. The company's liquidity position is rated as medium, with a current ratio of 0.68, suggesting limited short-term liquidity to cover immediate obligations. The enterprise value to EBITDA ratio is negative at -5.28, reflecting ongoing losses and a lack of positive cash flow generation.

Profitability metrics show a return on equity of 2.84%, which is unusually high given the negative equity, and a return on assets of -1.64%, indicating poor asset utilization and operational performance. These figures fall below the typical thresholds for a healthy medical equipment company, suggesting the firm is underperforming relative to industry norms.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, increasing exposure to market-specific risks. This lack of diversification could amplify the impact of any adverse developments in its core markets or product lines.

SeaStar Medical Holding Corp is currently experiencing a negative growth trajectory, with operating and net losses of -$3.95 million and -$12.70 million, respectively. Analysts have assigned a mean price target of $9.00, implying a potential upside of 116.67% from the current market price of $4.20. However, the absence of strong buy recommendations and the presence of a single buy recommendation suggest limited institutional confidence in the company's near-term prospects.

The company faces several risk factors, including a negative net cash position after subtracting total debt, which could constrain its ability to fund operations or pursue growth opportunities. The risk of dilution is currently rated as low, but the company's negative equity and high debt levels could necessitate future equity issuances, potentially diluting existing shareholders.

Recent filings and transcripts indicate ongoing operational challenges, including negative operating cash flow of -$3.49 million and a total equity deficit. These financial indicators suggest the company may need to secure additional financing or restructure its debt to remain solvent.

Key takeaways

SeaStar Medical Holding Corp is operating with a negative equity position and a high debt-to-equity ratio, indicating a leveraged capital structure.
The company's profitability metrics, including a negative return on assets, suggest poor operational performance.
Revenue concentration in a single segment and lack of geographic diversification increase business risk.
Analysts have assigned a mean price target of $9.00, implying a potential upside of 116.67% from the current market price.
The company faces liquidity and solvency risks due to negative operating cash flow and a negative net cash position.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-25

Q4 2025 · Quarter highlights

Open report →

Revenue $420.0k, +526,9% YoY; Operating income +36,7% YoY.

Revenue$420.0k+526,9 % YoY

Operating income-$3.0M+36,7 % YoY

Net income-$2.9M+34,3 % YoY

Free cash flow—

EPS—

Operating cash flow-$13.6M+15,0 % YoY

Financials

Income statement

Revenue$420.0k

Gross profit$408.0k

Operating income-$3.0M

Net income-$2.9M

Margins

Gross margin97.1%

Operating margin-718.1%

Net margin-691.4%

FCF margin—

Balance sheet

Total assets$14.2M

Total liabilities$3.7M

Total equity$10.4M

Cash & equivalents—

Long-term debt$525.0k

Cash flow

Operating cash flow-$13.6M

CapEx—

Free cash flow—

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue $420.0k, +526,9% YoY
▍Operating income +36,7% YoY
▍Net income +34,3% YoY
▍Net margin -691.4%

Valuation TTM

Market price

$4,22

Market cap

$16.8M

Enterprise valueⓘ

$20.8M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

16.9x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$4.5M

Net cashⓘ

-$4.1M

Current ratioⓘ

0.7

Debt / equityⓘ

-0.9

ROAⓘ

-1.6%

ROEⓘ

2.8%

Cash conversionⓘ

27.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships2 disclosed relationships · 2 types · extracted from filings & disclosures

Suppliers1

Fresenius SE & Co. KGaAFRE.DESupplier95%Source ↗

Partners1

Nuwellis IncNUWE.OPartner90%Source ↗

Supply chain

Vendors → ICU ↔ Partners → Customers · click any node to drill

2 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison8 peers · vs ICU · multiples and returns

ABT—

Abbott Laboratories

$107,13

187,2B USD

P/E

26,3x

— vs self

Div yield

2,4 %

— vs self

ROE

12,5 %

-271,3 vs self

MDT—

Medtronic PLC

$86,19

110,3B USD

P/E

21,4x

— vs self

Div yield

3,4 %

— vs self

ROE

9,7 %

-274,1 vs self

MDLN—

MEDLINE INC.

$40,47

53,2B USD

P/E

202,6x

— vs self

Div yield

—

— vs self

ROE

—

— vs self

SYK—

Stryker Corp

$341,20

131,8B USD

P/E

38,0x

— vs self

Div yield

—

— vs self

ROE

13,5 %

-270,3 vs self

BDX—

Becton Dickinson And Co

$170,21

48,4B USD

P/E

25,6x

— vs self

Div yield

2,8 %

— vs self

ROE

7,0 %

-276,9 vs self

HSIC—

Henry Schein Inc

$88,21

10,1B USD

P/E

80,5x

— vs self

Div yield

—

— vs self

ROE

3,0 %

-280,9 vs self

BAX—

Baxter International Inc

$28,10

14,5B USD

P/E

—

— vs self

Div yield

2,3 %

— vs self

ROE

-15,4 %

-299,3 vs self

SOLV—

SOLVENTUM CORPORATION

$76,83

13,3B USD

P/E

8,6x

— vs self

Div yield

—

— vs self

ROE

30,8 %

-253,0 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-3,25

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-3,25
Revenue	—no estimate	—no estimate	1,9M USD
Operating income	—no estimate	—no estimate	-14,7M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price target$9,00 · Median $9,00

Low $6,00High $12,00

Operating income · consensus-14,7M USD

EPS surprise

−80,3 %

reported vs consensus · miss

Revenue surprise

−34,0 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$6,00

Mean$9,00

Median$9,00

High$12,00

Spot$4,22

+113.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

ROE283,9 %Best in class

D/E-0,91Best in class

Cash Conv0,27Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 26 667 sh2 exercises2 insiders

Chung KevinChief Medical Officer · Restricted Stock Unit → Common Stock, par value $0.0001 per shareDisposed 5 000exercise · 2025-07-01
Schlorff EricDirector, Chief Executive Officer · Restricted Stock Unit → Common Stock, par value $0.0001 per shareDisposed 21 667exercise · 2025-07-01

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Enterprise Value
market_cap - net_cash

Source documents

SeaStar Medical Holding Corp Market data — financials · 2026-05-28
SeaStar Medical Holding Corp Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net buying5 buys · 0 sellsnet $45K8 insiders · last 365d

Van Heel KennethDirector · Common Stock, par value $0.0001Other 3 000 · 2026-02-06
Neuman JohnDirector · Common Stock, par value $0.0001Other 3 000 · 2026-02-06
Vincent Bernadette NDirector · Common Stock, par value $0.0001Other 3 000 · 2026-02-06
Baird Jennifer ADirector · Common Stock, par value $0.0001Other 3 000 · 2026-02-06
Towne Bradford KPrincipal Accounting Officer · Common Stock, par value $0.0001Other 7 500 · 2026-02-06
Chung KevinChief Medical Officer · Common Stock, par value $0.0001Other 15 000 · 2026-02-06
Schlorff EricChief Executive Officer · Common Stock, par value $0.0001Other 30 000 · 2026-02-06
Baird Jennifer ADirector · Common StockBought 4 200 @ $0,24$987 · 2025-12-19
Messinger MichaelChief Financial Officer · Common StockBought 14 500 @ $0,35$5K · 2025-12-09
Van Heel KennethDirector · Common Stock, par value $0.0001 per shareBought 10 000 @ $0,86$9K · 2025-08-27
Van Heel KennethDirector · Common Stock, par value $0.0001 per shareBought 25 000 @ $0,89$22K · 2025-08-26
Chung KevinChief Medical Officer · Common Stock, par value $0.0001 per shareBought 10 000 @ $0,80$8K · 2025-08-22

Short positioning

138.9Kshares short+69.6% vs prior

1days to cover

57.1%short of daily vol

248fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ICU.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSuppliersPartners

Evidence & claims

From filings & derived data

Gross margin (FY 2025-12-31): 95.7%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -45.3%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 91.2%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 814.1%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 774.8%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -17.4%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 31.8%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 15.0%Derived (calculated)
Net margin (FY 2025-12-31): -984.6%Derived (calculated)
Return on equity (FY 2025-12-31): -116.6%Derived (calculated)
Return on assets (FY 2025-12-31): -85.8%Derived (calculated)
Current ratio (FY 2025-12-31): 3.63xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.36xDerived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 51.1%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 577.1%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 204.0%Derived (calculated)
EPS (basic) (annual): USD-PER-SHARES -6SEC XBRL filing
Pre-tax income (annual): USD -12.15MSEC XBRL filing
Total operating expenses (annual): USD 13.36MSEC XBRL filing
Revenue (annual): USD 1.23MSEC XBRL filing
Total liabilities (annual): USD 3.74MSEC XBRL filing
Net income (annual): USD -12.15MSEC XBRL filing
Gross profit (annual): USD 1.18MSEC XBRL filing
Shareholders' equity (annual): USD 10.42MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-17FILINGFORM 8-K →

2026-05-13FILINGPROSPECTUS →

2026-05-13FILINGFORM 10-Q →

2026-05-13FILINGFORM 8-K →

2026-04-29FILINGFORM DEF 14A →

2026-04-28FILINGREGISTRATION STATEMENT →

2026-04-28FILINGFORM 8-K →

2026-03-25 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.4M · Net USD -2.9M

2026-03-25 16:05 UTCEARNINGSAnnual results — FY 2026 Revenue USD 1.2M · Net USD -12.2M

2026-03-25FILINGFORM 10-K →

2026-03-25FILINGFORM 8-K →

2026-02-06 00:00 UTCINSIDER7 insider transactions — 2026-02

2026-02-06INSIDERVan Heel Kenneth transacted 3.0k sh Common Stock, par value $0.0001 — Director

2026-02-06INSIDERNeuman John transacted 3.0k sh Common Stock, par value $0.0001 — Director

2026-02-06INSIDERVincent Bernadette N transacted 3.0k sh Common Stock, par value $0.0001 — Director

2026-02-06INSIDERBaird Jennifer A transacted 3.0k sh Common Stock, par value $0.0001 — Director

2026-02-06INSIDERTowne Bradford K transacted 7.5k sh Common Stock, par value $0.0001 — Principal Accounting Officer

2026-02-06INSIDERChung Kevin transacted 15.0k sh Common Stock, par value $0.0001 — Chief Medical Officer

2026-02-06INSIDERSchlorff Eric transacted 30.0k sh Common Stock, par value $0.0001 — Chief Executive Officer

2026-01-20FILINGFORM 8-K →

2025-12-19 00:00 UTCINSIDER2 insider transactions — 2025-12

2025-12-19INSIDERBaird Jennifer A bought 4.2k sh — Director ~$1k

2025-12-18FILINGFORM 8-K →

2025-12-09INSIDERMessinger Michael bought 14.5k sh — Chief Financial Officer ~$5k

2025-11-20FILINGFORM 424B5 →

2025-11-13 16:54 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 0.2M · Net USD -3.5M

2025-08-27 00:00 UTCINSIDER3 insider transactions — 2025-08

2025-08-27INSIDERVan Heel Kenneth bought 10.0k sh Common Stock, par value $0.0001 per share — Director ~$9k

2025-08-26INSIDERVan Heel Kenneth bought 25.0k sh Common Stock, par value $0.0001 per share — Director ~$22k

2025-08-22INSIDERChung Kevin bought 10.0k sh Common Stock, par value $0.0001 per share — Chief Medical Officer ~$8k

2025-08-13 16:05 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 0.3M · Net USD -2.0M

2025-07-10 00:00 UTCINSIDER8 insider transactions — 2025-07 2 derivative

2025-07-01INSIDERChung Kevin disposed of 5.0k sh Restricted Stock Unit — Chief Medical Officer

2025-07-01INSIDERSchlorff Eric disposed of 21.7k sh Restricted Stock Unit — Director, Chief Executive Officer

2025-06-30 00:00 UTCINSIDER10 insider transactions — 2025-06 4 derivative

2025-05-20 00:00 UTCINSIDER2 insider transactions — 2025-05

2025-05-14 16:05 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 0.3M · Net USD -3.8M

2025-04-01 00:00 UTCINSIDER2 insider transactions — 2025-04 2 derivative

Showing the 40 most recent of 44 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread